Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia

Frontline arsenic trioxide (ATO)–based treatment regimens achieve high rates of long-term relapse-free survival in treating acute promyelocytic leukemia (APL) and form the current standard of care. Refining prognostic estimates for newly diagnosed patients treated with ATO-containing regimens remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Epstein-Peterson, Zachary D., Derkach, Andriy, Geyer, Susan, Mrózek, Krzysztof, Kohlschmidt, Jessica, Park, Jae H., Rajeeve, Sridevi, Stein, Eytan M., Zhang, Yanming, Iland, Harry, Campbell, Lynda J., Larson, Richard A., Poiré, Xavier, Powell, Bayard L., Stock, Wendy, Stone, Richard M., Tallman, Martin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198910/
https://www.ncbi.nlm.nih.gov/pubmed/35349669
http://dx.doi.org/10.1182/bloodadvances.2021006682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198910/
https://www.ncbi.nlm.nih.gov/pubmed/35349669
http://dx.doi.org/10.1182/bloodadvances.2021006682

Ejemplares similares